Welcome to our dedicated page for Xilio Therapeutics news (Ticker: XLO), a resource for investors and traders seeking the latest updates and insights on Xilio Therapeutics stock.
Xilio Therapeutics, Inc. (XLO) is a clinical-stage biotechnology company pioneering tumor-activated therapies designed to target cancer precisely while reducing systemic side effects. This page serves as the definitive source for verified news and press releases related to XLO’s innovative immuno-oncology pipeline and strategic developments.
Investors and industry professionals will find timely updates on clinical trial progress, regulatory milestones, and research partnerships. Our curated collection includes announcements about XLO’s proprietary platform, engineered therapies (including cytokines, antibodies, and bispecifics), and collaborations advancing targeted cancer treatments.
Key updates cover advancements in tumor-activated IL-12, CTLA-4 inhibitors, and T cell engagers – all leveraging XLO’s focus on activating therapies exclusively within the tumor microenvironment. Bookmark this page to stay informed about developments that highlight the company’s scientific rigor and position in the competitive biotech landscape.
Xilio Therapeutics, a clinical-stage biotechnology firm, has announced the appointment of Dr. Aoife Brennan and Dr. James Shannon to its board of directors as of June 13, 2024.
Dr. Brennan brings over 16 years of industry leadership, having held executive roles at Synlogic and Biogen, while Dr. Shannon has over 30 years of experience, previously serving as chief medical officer at GlaxoSmithKline and holding leadership positions at Novartis.
Their extensive expertise is expected to significantly contribute to Xilio's ongoing development of novel, tumor-activated immuno-oncology therapies, with several clinical milestones anticipated in the near term.
Xilio Therapeutics (NASDAQ: XLO) announced significant pipeline and business updates alongside its Q1 2024 financial results. Highlighting their progress, they plan to initiate a Phase 2 trial for XTX101, an Fc-enhanced anti-CTLA-4, in combination with atezolizumab for MSS CRC in Q3 2024, and report clinical data in Q4 2024. The XTX301 IL-12 program, partnered with Gilead Sciences, received $43.5M upfront and is set for Phase 1 data release in Q4 2024. Furthermore, Xilio's research efforts on bispecifics and immune cell engagers are advancing. Financially, Xilio ended Q1 2024 with $34M in cash, supplemented by an additional $44.6M from Gilead agreements and private placements, projecting a cash runway until Q2 2025.
FAQ
What is the current stock price of Xilio Therapeutics (XLO)?
What is the market cap of Xilio Therapeutics (XLO)?
